Skip to content

Are You Prepared For Questions About Medical Cannabis?

Are You Prepared For Questions About Medical Cannabis?

With over 85% of Americans supporting legalizing medical cannabis, it’s inevitable that patients will begin asking their primary care doctors about its use and overall efficacy. Doctors and other medical professionals will be called upon to be ‘sense-makers’ for a treatment they never studied in medical school and have limited available research to draw upon.  It’s a very challenging problem made more complex by the fact that medical cannabis use in individuals 65 and older increased 75% in the last 4 years, leaving many to wonder if there are any negative effects resulting from interactions with other medications. 

We at Arfinn Med understand the complexity of this issue and have released an updated version of our software to address this gap.  In addition to our EMR, completely online patient intake process, and telehealth solutions, we now have the ability to track patient outcomes dynamically through SMS updates, a customizable patient portal, and data fields specifically for cannabis patients.  This information will help medical professionals assist their patients throughout the whole process including efficacy review data on dispensaries and product type.     

We will also allow medical professionals with split practices to embed our platform in their existing EMR software so they can query our database of deidentified efficacy data for any patient demographic or condition. This will allow our users to confidently recommend cannabis to their patients with actual point-of-care analytics while keeping cannabis patients separate from the general patient population.  This will ensure cannabis patients will receive the proper follow-up and monitoring. 

If you’re looking for easy to use practice management software and a robust EMR, please reach out to us at info@arfinnmed.com to learn how we put the power of data into your patient care.      

Stories you may be interested in

CEO Spotlight: James West

As a former academic coordinator for the City University of New York Research Foundation and Medgar Evers College, CEO and co-founder of Arfinn Med, James West, has extensive experience in adult education and professional training programming. James put this extensive education to good use when he noticed that there was a direct need for a…
Read More

Cannabis and autism, explained

Over the past decade, autistic people and their families have increasingly experimented with medical marijuana and products derived from it. Many hope these compounds will alleviate a range of autism-related traits and problems. But scientists are still in the early stages of rigorous research into marijuana’s safety and effectiveness, which means that people who pursue…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

Survey of oncologists finds knowledge gap on medical marijuana

As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers. Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial…
Read More

Texas House Bill 3703: What You Need to Know

The state of Texas has been in the news in recent months as the legislature review House Bill 3703. This bill relates to “the prescription of low-THC cannabis for medical use by certain qualified physicians to patients with [specific] qualifying conditions”. Originally filed in March of 2019, this bill made its way through the house…
Read More

Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders

Report of the Guideline Development Subcommittee of the American Academy of Neurology:   We performed a systematic review of medical marijuana (1948–November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. Read the full…
Read More

Leave a Comment

You must be logged in to post a comment.